DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer
Ryoichi Matsunuma(Hamamatsu University School of Medicine), Matthew J. Ellis(Guardant (United States)), Doug W. Chan(Baylor College of Medicine), Mei Leng(Baylor College of Medicine), Airi Han(Baylor College of Medicine), Alexander B. Saltzman, Jonathan T. Lei(Baylor College of Medicine), Charles M. Perou(University of North Carolina at Chapel Hill), Ergün Sahin(Harvard University), Junkai Wang(Baylor College of Medicine), Beom‐Jun Kim(Ulsan College), Leonardo Roberto da Silva(Universidade Estadual de Campinas (UNICAMP)), Cheng Fan(University of North Carolina at Chapel Hill), Purba Singh(Baylor College of Medicine), Chonghui Cheng(Baylor College of Medicine), Anna Malovannaya(Baylor College of Medicine)
Cited by 65
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k